
Medicamen Biotech Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
2026-11-16 10:00:25At Rs 295.7, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Medicamen Biotech Ltd locked at its upper circuit of 5% on 16 Nov 2026, with buyers queuing and no sellers willing to part with shares.
Read MoreMedicamen Biotech Gains 7.79%: Downgrade and Lower Circuit Mark a Volatile Week
2026-11-07 16:00:08Key Events This Week 2 Nov: Stock opens strong at Rs.264.25 (+3.42%) 3 Nov: Downgrade to Sell and hits lower circuit at Rs.247.10 (-5.00%) 4 Nov: Modest recovery to Rs.263.90 (+0.61%) 6 Nov: Strong rally closes week at Rs.275.40 (+4.95%) Week OpenRs.255.50 Week CloseRs.275.40<div class="s...
Read More
Medicamen Biotech Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight
2026-11-03 15:00:08At Rs 247.1, sellers were still queuing — but there were no buyers willing to take the other side. Medicamen Biotech Ltd locked at its lower circuit of 5.0% on 03 Nov 2026, with unfilled sell orders and a frozen price.
Read More
Medicamen Biotech Ltd is Rated Hold by MarketsMOJO
2026-11-02 10:10:02Medicamen Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 October 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Medicamen Biotech Ltd Valuation Shifts to Fair Amidst Weak Returns
2026-10-28 08:00:45Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in market perception. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios indicate a more cautious stance among investors amid subdued returns and sector headwinds.
Read MoreMedicamen Biotech Ltd Falls 11.42%: 4 Key Factors Driving the Weekly Decline
2026-10-24 16:00:35Key Events This Week 19 Oct: Stock opens at ₹272.65, down 4.82% 21 Oct: Golden Cross formation and valuation upgrade; stock closes at ₹263.65 (-3.30%) 22 Oct: Mild recovery with 1.23% gain to ₹266.90 23 Oct: Hits lower circuit, closes at ₹253.75 (-4.93%) Week Open₹286.45 Week Close₹253.75...
Read More
Medicamen Biotech Ltd Upgraded to Hold on Improved Technicals and Valuation
2026-10-22 08:21:48Medicamen Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite ongoing challenges in financial performance and long-term returns, the company’s improved technical indicators and more attractive valuation relative to peers have prompted a reassessment of its market stance as of 21 October 2026.
Read More
Golden Cross Forms in Medicamen Biotech Ltd — On a Day the Stock Fell 3.3%. What the Mixed Signals Mean
2026-10-21 18:00:26The 50-day moving average has crossed above the 200-day moving average for Medicamen Biotech Ltd, signalling a golden cross on 21 Oct 2026. Yet, the stock declined 3.3% on the same day, and the broader technical indicators present a mixed picture, raising questions about the signal’s reliability.
Read More
Medicamen Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges
2026-10-21 08:01:50Medicamen Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite ongoing sector headwinds and a recent share price decline. This repositioning, driven by improved price-to-earnings and price-to-book value metrics relative to peers, offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEAnnouncement under Regulation 30 (LODR)- Newspaper Publication
Financial Results - Quarter And Half Year Ended On September 30 2026
13-Nov-2026 | Source : BSEFinancial Results - Quarter and Half year ended on September 30 2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On September 30 2026.
06-Nov-2026 | Source : BSEMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 inter alia to consider and approve the unaudited financial results for the quarter and half year ended on September 30 2026.
Corporate Actions
No Upcoming Board Meetings
Medicamen Biotech Ltd has declared 10% dividend, ex-date: 18 Sep 26
No Splits history available
No Bonus history available
No Rights history available